Editorial Council discusses the pharmacopoeial monographs for Volume 2 of the second edition of the State Pharmacopoeia
On 29 October 2026, the 10th meeting of the Editorial Council, chaired by the Editor-in-Chief of the State Pharmacopoeia, Professor Kh.K. Djalilov, discussed 165 individual pharmacopoeial monographs for Volume 2 of the second edition; 33 are included for the first time.
On 29 October 2026, the 10th regular meeting of the Editorial Council of the State Pharmacopoeia of the Republic of Uzbekistan was held in a hybrid format at the "Center for Safety of Pharmaceutical Products" State Institution.
The meeting was chaired by the Editor-in-Chief of the State Pharmacopoeia of the Republic of Uzbekistan and Chairman of the Editorial Council, Doctor of Pharmaceutical Sciences, Professor Kh.K. Djalilov. It was attended by members of the Editorial Council and representatives of the Specialized Expert Commissions.
The meeting reviewed the work on compiling Volume 2 of the second edition of the State Pharmacopoeia. The report by Kh.K. Djalilov covered all 165 individual pharmacopoeial monographs planned for inclusion in Volume 2. Of these, 33 are being included in the State Pharmacopoeia for the first time. The remaining 132 were present in the previous edition and have been revised by the Secretariat of the State Pharmacopoeia with partial amendments and additions. The content of the monographs, their compliance with the requirements of the European Pharmacopoeia and the United States Pharmacopeia, and their adaptation to national practice were discussed in detail.
The Scientific Secretary of the Editorial Council and Chief Specialist of the State Pharmacopoeia Development Department, A.Kh. Mansurov, presented the results of monitoring the pharmacopoeial monographs submitted to the Specialized Expert Commissions. It was noted that 70 monographs are currently under review by the expert commissions: 58 of them are at the development stage and 12 at the scientific editing stage. The report set out the current status of the work for each commission and proposals for accelerating the review process.
The participants held a comprehensive exchange of views on the reports, and relevant decisions were adopted on all items of the agenda.
The issues considered at the meeting contribute to the consistent development of the State Pharmacopoeia in line with international requirements and to updating the national standards for assessing the quality of medicines. They are also aimed at providing the population with high-quality, safe and effective medicines.